A protein drug for treatment of Cronic and diabetic wounds
| Reference number | |
| Coordinator | Umeå Biotech Incubator AB |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | May 2012 - December 2014 |
| Status | Completed |
Purpose and goal
The objective was to develop plasminogen to a drug for the treatment of diabetic wounds. The goal was to either (1) sign an exclusive license agreement with a company, (2) Being able to find capital to drive the project forward to the initiate clinical studies, or (3) to find a partner that can fund its future operations in a joint venture. Fulfillment: During the project period we have worked with different approaches. What proved most successful was to sign an exclusive license agreement with an industrial player. This work is currently underway.
Expected results and effects
We agree with an industrial player on the outline of a licensing agreement where we together with this operator plan to perform clinical trials in both diabetic wounds and other indications. This operator produces plasminogen by GMP quality and we stand for IP and know-how.
Planned approach and implementation
The agreement is now being developed and is based on that we carry out preclinical research to test out new indications, and that we together with our industriell partner performs clinical trials. The product will be marketed by the industriell partner and we will receive milestone as well as royalty payments.